Tikun Olam and MariMed Inc. have agreed to expand their partnership which will see Tikun-branded products rolled out in Rhode Island, Maryland, Massachusetts, and Illinois next year. The partnership brought the company’s products to Delaware in 2015.
The companies expect to offer at least six Tikun-branded strains, including high-CBD strain Avidekel, along with tinctures, edibles, vape cartridges, and edibles.
“Tikun Olam is delighted to expand our relationship with MariMed,” said Tikun CEO Bernard Sucher in a press release. “MariMed utilizes the ‘best practices’ and standards for cultivation and production and their qualified distribution channels allow us to bring our proven wellness products to more U.S. patients than ever before.”
Tikun Olam, a medical cannabis provider in Israel, announced in April that they were expanding their U.S. reach into Nevada with a partnership with CW Nevada LLC. They plan to begin offering products in Washington state in November.
MariMed CEO Robert Fireman said the agreement is due, in part, to the “great success” of the Delaware pilot program.
“Tikun Olam’s empirical data on clinical effectiveness is unsurpassed, and we look forward to educating healthcare professionals and offering Tikun’s products to tens of thousands of new patients nationwide,” he said in a statement.
Since 2010, Tikun’s clinical data has shown that the firm’s strains are effective therapies for symptomatic relief of cancer, post-traumatic stress disorder, Crohn’s disease, colitis, epilepsy, neuropathy, and chronic pain. The company has treated over 10,000 patients in Israel.